BMY Stock Today, March 8: First Trust Boosts Stake as Peers Trim

Bristol Myers Squibb stock is in focus for Canadian investors after new 13F data showed a split among big funds. First Trust boosted exposure while others trimmed, setting the stage for flow-driven moves. At USD 60.29 and a 4.13% dividend yield, the setup mixes income with pipeline risk ahead of Q1 results on April 30. We track symbol BMY, where valuation, dividends, and technicals point to balanced risk and reward today. Canadians buying US shares should consider FX costs and how RRSPs treat US dividends versus TFSAs. Institutional positioning and steady cash flows may drive near-term direction.

Institutional moves: what filings say now

Q3 filings show First Trust Advisors lifted its position by 22.6%, adding about 1.0 million shares source. Edgar Lomax and Kahn Brothers reduced holdings, highlighting mixed conviction among value managers source. When institutional ownership moves in opposite directions, near-term trading can skew to headlines and factor flows. That creates a sensitive backdrop for any pipeline or guidance updates.

With shares at USD 60.29, P/E 17.42, dividend yield 4.13%, and market cap about USD 122.76B, the flow signal lands as fundamentals sit mid-range. A recent EPS miss keeps sentiment fragile, so net buying or selling by funds can tilt momentum. Technicals show ADX 35.10 and RSI 52.65, while MACD’s histogram is slightly negative, favoring range trading unless flows intensify.

For Canadians, FX costs and account choice matter. RRSPs typically avoid U.S. withholding on U.S.-listed dividends, while TFSAs and taxable accounts usually see 15% withheld under the treaty. Confirm your broker’s DRIP rules for fractional reinvestment. Liquidity on NYSE is strong, yet limit orders can help around spreads. Track institutional ownership updates, which can sway borrow costs and short interest.

Dividend, valuation, and balance sheet check

The BMY dividend yield stands near 4.13% on a USD 2.49 TTM payout. The payout ratio is 71.5%, supported by free cash flow per share of USD 6.29 and operating cash flow per share of USD 6.94. Dividend plus capex coverage sits at 2.23x, while the current ratio is 1.26. For income investors, that signals reasonable sustainability if cash generation holds.

Valuation is moderate for big pharma: P/E 17.37, price-to-sales 2.54, and EV/EBITDA 10.97. Price-to-book at 6.63 reflects heavy intangibles. Profitability metrics are strong, with ROE at 39.27%, partly leverage-driven. Debt-to-equity is 2.55 and interest coverage is 8.41, so deleveraging would enhance resilience if growth slows. Overall, returns look solid if margins and cash flow persist.

R&D intensity near 19.94% of revenue and a 26.34% operating margin show continued investment alongside efficiency. Flagship therapies like Eliquis and Opdivo support cash flow, while cell therapy assets contribute diversification. After a recent EPS miss, pipeline milestones, label expansions, and guidance updates carry extra weight. Any clarity on growth drivers or debt plans could reset sentiment quickly.

Price action and technical setup

Price sits above the 50-day (USD 57.43) and 200-day (USD 49.72) averages, keeping the primary trend constructive. RSI at 52.65 is neutral, while ADX at 35.10 indicates a strong underlying trend. MACD’s histogram is slightly negative, hinting at waning momentum. MFI at 53.92 suggests balanced flows. Together, the picture favors patient entries over momentum chasing.

Near-term, the lower Bollinger Band at 59.39 and day low 59.45 mark initial support. Resistance sits near the upper band at 62.59 and the 1-year high at 63.33. ATR at 1.37 implies typical daily swings of about USD 1.37. Performance remains firm: 3M +15.59%, 6M +27.87%, YTD +12.76%, and 1Y +0.17%.

Earnings are slated for April 30, 2026. Until then, watch a break above 62.59 for continuation, or a slip below 59.39 for a deeper pullback toward the 50-day. Position sizing using ATR of 1.37 can help manage risk. Options traders may prefer defined-risk spreads given mixed momentum signals.

Street views, grades, and scenarios

Wall Street is split: 13 Buy, 13 Hold, and 2 Sell, with a consensus of 3.00. Independent models show an A- Company Rating with a Buy tilt, while Meyka’s Stock Grade is B+ with a BUY suggestion. The message is balanced optimism. Catalysts, not sentiment, likely drive the next leg.

Model paths sit below spot: monthly USD 58.69, quarterly USD 42.30, and 12-month USD 50.55. Longer-term projections cluster around USD 49–51. While helpful for planning, these are guideposts, not guarantees. Investors should blend forecasts with cash flow strength, dividend history, technical levels, and upcoming clinical or regulatory milestones.

Three levers could matter most: steady cash conversion (FCF yield about 10.47%), visible deleveraging from today’s 2.55 debt-to-equity, and tangible pipeline or label progress. Any improvement here could compress risk premia. Conversely, slower growth or pricing pressure would likely push multiples toward forecast paths and keep Bristol Myers Squibb stock range-bound.

Final Thoughts

Institutional signals are split, with First Trust adding while peers trim. That leaves Bristol Myers Squibb stock sensitive to fund flows as it offers a 4.13% yield, mid-teens P/E, and neutral momentum. For Canadians, account choice and FX costs matter as much as entry price. We would track support at 59.39–59.45 and resistance near 62.59–63.33 into the April 30 earnings date. A constructive setup likely needs one of two things: clearer pipeline progress or evidence of deleveraging with steady free cash flow. Until then, scaling entries on weakness and reinvesting dividends can keep risk controlled while preserving upside optionality.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.